Welcome to our dedicated page for Accelerate Diagnostics news (Ticker: AXDX), a resource for investors and traders seeking the latest updates and insights on Accelerate Diagnostics stock.
Accelerate Diagnostics, Inc. (AXDX) generates news that spans product development in rapid in vitro diagnostics, regulatory milestones, financial performance, and significant corporate restructuring events. Company press releases describe a focus on solutions for antibiotic resistance and sepsis, with updates on platforms such as the Accelerate Pheno system, Accelerate PhenoTest ae BC kit, the FDA-cleared Accelerate Arc ae system and BC kit, and the development-stage Accelerate WAVE ae system.
News coverage frequently highlights clinical and regulatory progress. For example, the company has announced 510(k) clearance of the Accelerate Arc system and BC kit and the submission of the Accelerate WAVE system and Gram-negative positive blood culture test kit to the U.S. Food and Drug Administration for 510(k) clearance. Other releases describe successful pre-clinical and clinical trial milestones for the WAVE system, including performance data compared to broth microdilution reference methods and time-to-result metrics intended to support same-shift antimicrobial susceptibility reporting.
Financial news from Accelerate Diagnostics includes quarterly and full-year results, with details on net sales, gross margin, operating expenses, research and development spending, and net loss. The company has also reported on financing activities, such as debt issuances and debtor-in-possession financing commitments, as well as decisions about investor communications, including changes to its practice of hosting regular earnings conference calls.
A major theme in recent news is the companys Chapter 11 restructuring. Press releases and related SEC filings describe the voluntary Chapter 11 petitions filed in the United States Bankruptcy Court for the District of Delaware, a court-supervised sale process under Section 363 of the Bankruptcy Code, and an asset purchase agreement with an affiliate of Indaba Capital Management, L.P. Subsequent updates discuss court approval of the sale transaction, amendments to the asset purchase agreement, and confirmation of a Chapter 11 Plan of Liquidation that provides for cancellation of existing equity interests.
Visitors to this news page can review historical announcements on product clearances, trial results, financial performance, capital structure changes, and the progression of the Chapter 11 cases and asset sale. This context helps investors and observers understand how Accelerate Diagnostics diagnostic platforms and corporate structure have evolved over time.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced three data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), occurring July 9–12, 2021. The study evaluates the Accelerate Pheno system's impact on bloodstream infection treatment across multiple hospitals. Key findings include a statistically significant reduction in 30-day mortality (6.0% in AXDX vs. 15.9% in SOC) for patients receiving ineffective empirical treatment. The presentations highlight improved microbiology test turnaround times and antimicrobial use.
Accelerate Diagnostics (NASDAQ: AXDX) will participate in the William Blair 41st Annual Growth Stock Conference on June 3, 2021, at 12:00 p.m. Central Time. CEO Jack Phillips and CFO Steve Reichling will present virtually, and a live audiocast will be available on the company's investor relations website. The company specializes in in vitro diagnostics, focusing on solutions for antibiotic resistance and sepsis, with its Accelerate Pheno® system providing faster results for antibiotic susceptibility testing.
Accelerate Diagnostics, Inc. (AXDX) announced its Q1 2021 financial results, reporting net sales of $2.5 million, an 8% increase from Q1 2020. The company added 2 contracted instruments, ending with 274 revenue-generating instruments in the U.S. However, instrument revenue fell, while consumables rose by 16%. Gross margins dropped to 36% from 45% due to pandemic-related costs. Net loss was $24.2 million or $0.41 per share. SG&A costs increased to $14.0 million, but adjusted costs decreased. The company closed on the first of three $10.7 million financing tranches.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) will host a conference call on May 6, 2021, at 4:30 p.m. Eastern Time to discuss its 2021 first quarter financial results. Interested participants can join by phone at +1.877.883.0383, entering Elite Entry Number: 4747452, or listen via webcast at ir.axdx.com. A replay will be accessible via phone and the website until August 6, 2021, and May 27, 2021, respectively. Accelerate Diagnostics focuses on solutions for antibiotic resistance and sepsis through its FDA-cleared systems that expedite antibiotic susceptibility testing.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) reported a net sales of $3.1 million for Q4 2020, reflecting a 10% decline year-over-year, while full-year sales grew by 20% to $11.2 million. The net loss for Q4 was $18.9 million, resulting in a loss of $0.33 per share. The gross margin for Q4 was 37% compared to 44% in the same quarter of 2019. Despite pandemic-related challenges impacting new instrument placements, the company saw a 63% increase in revenue-generating installed base for 2020. Total cash and equivalents stood at $68.3 million at year-end.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) has scheduled a conference call for February 23, 2021, at 4:30 p.m. Eastern Time, to discuss the financial results for the fourth quarter and full year 2020. The call will provide insights into the company’s performance, focusing on their in vitro diagnostics solutions aimed at combating antibiotic resistance and sepsis. An audio webcast will be available at ir.axdx.com, and a replay will be accessible until May 24, 2021.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time. A live audiocast will be available on the company’s investor relations website, with a replay provided for at least 30 days post-conference.
The company focuses on combating antibiotic resistance and sepsis through its Accelerate Pheno® system and Accelerate PhenoTest® BC kit, delivering phenotypic antibiotic susceptibility results in approximately 7 hours.
Accelerate Diagnostics (NASDAQ: AXDX) reported preliminary financial results for Q4 and full year 2020, highlighting a total revenue of approximately $3.1 million for Q4, down from $3.5 million year-over-year, but up to $11.2 million for the full year compared to $9.3 million in 2019. The company placed 45 new instruments in Q4, raising the total to 268 in the U.S., with a backlog of 133 instruments. Gross margin for 2020 is expected at 40%, with net cash used around $41 million, leaving a cash balance of $100 million post-financing. Management remains optimistic about 2021 sales and product launches.
Accelerate Diagnostics (AXDX) reported third-quarter 2020 revenues of $3.6 million, a 57% increase from the previous year. The company ended the quarter with 223 live revenue-generating Pheno instruments in the U.S. However, gross margin fell to 36% due to pandemic-related manufacturing impacts. Year-to-date net sales reached $8.1 million, a 40% rise compared to 2019. The net loss for the quarter was $18.8 million, or $0.33 per share. Cash and equivalents stood at $77.5 million. The company received FDA approvals for key product enhancements, which are expected to stimulate customer interest.
Accelerate Diagnostics, Inc. will host a virtual Investor Product Demo Day on October 20, 2020, at 11:00 a.m. Eastern Time. This event offers insights into the Company's product strategy and features live demonstrations and a Q&A with CEO Jack Phillips. Pre-registration is required by October 19, 2020. Additionally, a conference call reviewing the third quarter financial results is scheduled for November 5, 2020, at 4:30 p.m. Eastern Time.